20:49 , Aug 29, 2018 |  BC Innovations  |  Emerging Company Profile

Meta(bolite) analysis

ClostraBio Inc.’s preclinical gut microbiome-derived metabolites could yield a pan-allergen therapy for food allergy, eschewing the need for multiple allergen-specific treatments. Director of Operations John Colson said research from co-founder and President Cathryn Nagler suggests microbial...
22:10 , Aug 3, 2018 |  BC Extra  |  Politics & Policy

ICER announces preliminary 2019 topics

The Institute for Clinical and Economic Review (ICER) released Thursday a preliminary list of drugs and other healthcare interventions that it may review in 2019. ICER's selection criteria include the projected timing and likelihood of...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
20:25 , Feb 23, 2018 |  BC Week In Review  |  Financial News

Aimmune raises $176M in bumped up follow-on

Allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised $176 million on Feb. 22 through the sale of 5.5 million shares at $32 in a bumped-up follow-on. Underwriters were BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit...
22:44 , Feb 22, 2018 |  BC Week In Review  |  Clinical News

Aimmune's peanut allergy therapy meets in Phase III

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said AR101 met the primary endpoint in the Phase III PALISADE trial to treat peanut allergy, but also reported that a greater proportion of patients in the active arm discontinued treatment...
20:03 , Feb 22, 2018 |  BC Extra  |  Financial News

Ascendis, Aimmune price upsized follow-ons

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) and allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised a total of $401 million late Wednesday in bumped-up follow-ons. Ascendis raised $225 million through the sale of 3.9 million ADSs at...
23:06 , Feb 20, 2018 |  BC Extra  |  Clinical News

Aimmune's peanut allergy therapy meets in Phase III

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said AR101 met the primary endpoint in the Phase III PALISADE trial to treat peanut allergy, but also reported that a greater proportion of patients in the active arm discontinued treatment...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:09 , Oct 20, 2017 |  BC Extra  |  Clinical News

DBV peanut allergy treatment fails Phase III study

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) plummeted $25.17 (52%) to $22.90 in after-hours trading on NASDAQ Friday after it said Viaskin Peanut (DBV-712) missed the primary endpoint in the Phase III PEPITES trial to treat peanut...
00:33 , Oct 20, 2017 |  BC Week In Review  |  Company News

Aimmune, Regeneron teaming up for peanut allergy trial

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said it will collaborate with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) to conduct a Phase II combination trial to treat peanut allergy. The trial, anticipated to begin next year,...